Industry Insight | Cellares Expands Automated Cell Therapy Manufacturing Into Europe

May 2026 - Cellares has announced the European launch of its automated Cell Shuttle™ manufacturing platform, marking another step toward large-scale industrialization of cell therapy production.

According to the company, the expansion aims to support growing global demand for scalable manufacturing of advanced therapies including CAR-T and other engineered immune cell products. The Cell Shuttle™ platform is designed to automate multiple manufacturing steps within a closed system, helping reduce labor requirements, improve process consistency, and lower production costs.

Photo by Hans Reniers on Unsplash

The move reflects a broader industry trend as cell therapy developers increasingly invest in automation and standardized manufacturing workflows. As more therapies progress into late-stage clinical trials and commercialization, production scalability has emerged as one of the sector’s biggest operational challenges.

Industry observers note that automated manufacturing platforms could play a major role in improving global access to cell therapies by shortening production timelines and enabling larger patient volumes. This is particularly important for rapidly growing areas such as NK and CAR-NK therapies, where efficient cell expansion and reproducible manufacturing processes remain critical bottlenecks.

At the same time, recent research continues to focus on improving NK-cell functionality and persistence in solid tumors. Scientists are exploring new genetic engineering strategies and expansion technologies aimed at enhancing NK-cell survival and anti-tumor activity within the tumor microenvironment.

Photo by Testalize.me on Unsplash 

As the field continues to evolve, technologies supporting scalable immune-cell manufacturing—including optimized expansion systems and feeder-cell platforms—are expected to become increasingly important across both research and commercial production settings.

Companies such as Hillgene Biopharma are contributing to this ecosystem through engineered K562 feeder cell platforms designed for NK and CAR-NK cell expansion workflows.

Sources:

Cellares European platform launch announcement (May 2026)

Reported by Business Wire and coverage from CRISPR Medicine News